Form 4: BioMarin Pharmaceutical Inc. Executive Erin Burkhart Reports Stock Transactions
SEC Form 4 Filing
Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the disposition of common stock on May 19 and 20, 2025, according to a Form 4 filing.
Summary
- On May 19, 2025, Erin Burkhart, the GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., disposed of 996 shares of common stock at a price of $59.27.
- On May 20, 2025, Burkhart sold 1,786 shares of common stock at $59.31 per share.
- Following these transactions, Burkhart directly owns 14,173 shares of BioMarin Pharmaceutical Inc.
- The sale on May 20, 2025, was executed under a pre-arranged 10b5-1 trading plan established on November 26, 2024.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by an executive. The use of a 10b5-1 plan indicates pre-planned sales, which is neutral.
Industry Context
Executive stock transactions are a normal part of corporate governance and are publicly disclosed to ensure transparency. The use of a 10b5-1 plan suggests the executive planned these transactions in advance to avoid any accusations of insider trading.
Stakeholder Impact
- The stock sales by a company executive could be perceived negatively by shareholders if not understood in the context of pre-planned trading.
Key Dates
| Date | Description |
|---|---|
| 2024-11-26 | Date of execution of the 10b5-1 trading plan. |
| 2025-05-19 | Date of the first reported transaction: disposition of 996 shares. |
| 2025-05-20 | Date of the second reported transaction: sale of 1,786 shares. |
Keywords
Form 4, BioMarin Pharmaceutical Inc., BMRN, Erin Burkhart, Stock Sale, 10b5-1 Plan, GVP, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.